374 related articles for article (PubMed ID: 28545541)
1. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
[TBL] [Abstract][Full Text] [Related]
4. Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.
Connor EV; Saygin C; Braley C; Wiechert AC; Karunanithi S; Crean-Tate K; Abdul-Karim FW; Michener CM; Rose PG; Lathia JD; Reizes O
J Ovarian Res; 2019 Nov; 12(1):112. PubMed ID: 31735168
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract][Full Text] [Related]
6. Cancer Stem Cell Properties as Factors Predictive of Chemoresistance in Neoadjuvantly-treated Patients with Ovarian Cancer.
Pylväs-Eerola M; Liakka A; Puistola U; Koivunen J; Karihtala P
Anticancer Res; 2016 Jul; 36(7):3425-31. PubMed ID: 27354603
[TBL] [Abstract][Full Text] [Related]
7. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
8. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
[TBL] [Abstract][Full Text] [Related]
9. The ALDH1⁺ subpopulation of the human NMFH-1 cell line exhibits cancer stem-like characteristics.
Li D; Zhang T; Gu W; Li P; Cheng X; Tong T; Wang W
Oncol Rep; 2015 May; 33(5):2291-8. PubMed ID: 25760144
[TBL] [Abstract][Full Text] [Related]
10. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas.
He QZ; Luo XZ; Wang K; Zhou Q; Ao H; Yang Y; Li SX; Li Y; Zhu HT; Duan T
Cell Physiol Biochem; 2014; 33(1):173-84. PubMed ID: 24504111
[TBL] [Abstract][Full Text] [Related]
12. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
13. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
[TBL] [Abstract][Full Text] [Related]
14. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
[TBL] [Abstract][Full Text] [Related]
15. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Puopolo M; Yu H
Oncol Res; 2007; 16(8):395-403. PubMed ID: 17913048
[TBL] [Abstract][Full Text] [Related]
16. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
17. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
18. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
19. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
